Beta-lactam antibiotic administration in critically ill children with sepsis: an international survey of current practice
Authors:
- Sainath RamanSRSainath Raman
- the Australian and New Zealand Intensive Care Society Paediatric Study GroupTGthe Australian and New Zealand Intensive Care Society Paediatric Study Group
- Tatjana KerigTKTatjana Kerig
Open Access
- 10 June 2025
- journal article
- research article
- Published by Springer Nature in Intensive Care Medicine – Paediatric and Neonatal
- Vol. 3 (1) , 1-6
Abstract
Objective: To assess current international practices and perceptions regarding beta-lactam antibiotic administration in critically ill children with sepsis. Design, setting, and participants: An electronic survey was distributed among physicians, advanced nurse practitioners and pharmacists working in paediatric intensive care units (PICUs) through PICU research networks from April to August 2024. Main outcome measures: Demographic characteristics, current practices of beta-lactam (meropenem, piperacillin/tazobactam and cefotaxime) administration, reasons for infusion method choices, and perceptions on the efficacy of continuous and extended infusions. Results: Two hundred sixty clinicians responded (236 physicians, 21 pharmacists, 2 advanced nurse practitioners) from 18 countries and 5 continents. Most respondents (88.1%) indicated use of beta-lactams as first-line antibiotics for children with sepsis, with intermittent infusion as the predominant standard practice across the selected beta-lactams (meropenem, 50.2%; piperacillin/tazobactam, 68.5%; and cefotaxime, 82.8%). Among respondents who opted for a continuous or extended infusion on an individual patient basis, 55.0% cited higher severity of illness as the primary reason for choosing this method for meropenem. The majority of respondents (86.5%) agreed there is lack of evidence to embed continuous and/or extended beta-lactam infusions into clinical practice and would recruit (84.6%) to a randomised controlled trial comparing continuous and/or extended and intermittent infusion. Conclusions: This international survey highlights the lack of evidence in beta-lactam administration practices in treating critically ill children with sepsis. There is a clear need and desire for further research through randomised controlled trials to establish optimal beta-lactam infusion methods and investigate their impact on clinical outcomes in the paediatric patient population.Keywords
This publication has 18 references indexed in Scilit:
- Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With SepsisJAMA, 2024
- Prolonged vs Intermittent Infusions of β-Lactam Antibiotics in Adults With Sepsis or Septic ShockJAMA, 2024
- Optimizing the Value of β-Lactam Antibiotics Through Extended InfusionJAMA Network Open, 2024
- Pharmacokinetic parameters over time during sepsis and the association of target attainment and outcomes in critically ill children and young adults receiving ceftriaxonePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2023
- Are β-lactam concentrations adequate in severe sepsis and septic shock in children?Therapies, 2020
- Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease StudyThe Lancet, 2020
- Vancomycin Use in a Paediatric Intensive Care Unit of a Tertiary Care HospitalPediatric Drugs, 2019
- Should β-lactam antibiotics be administered by continuous infusion in critically ill patients? A survey of Australia and New Zealand intensive care unit doctors and pharmacistsInternational Journal of Antimicrobial Agents, 2016
- Mortality related to invasive infections, sepsis, and septic shock in critically ill children in Australia and New Zealand, 2002–13: a multicentre retrospective cohort studyThe Lancet Infectious Diseases, 2015
- Dose optimisation of antibiotics in children: application of pharmacokinetics/pharmacodynamics in paediatricsInternational Journal of Antimicrobial Agents, 2014